The drug Cymbalta was a big seller for Eli Lilly and generated about $5 billion in sales just last year. Duloxetine is the name of the generic equivalent. As you can see here Lupin Pharma is right out there and others like Teva are expected to be marketing their generic versions of the drug as well which is used to treat anxiety and depression and pain related to muscles and bones. The drug is a selective serotonin inhibitor and is manufactured in 3 strengths, 20 mg, 30 mg, and 60 mg capsules.
For those taking the drug it sounds like the cost is going to be a little more affordable. Drug companies are facing expiring patents and this is one that is probably going to have an impact on Eli Lilly. In addition Cymbalta has produced a few lawsuits over deceptive advertising and the fact that it is stated to be related to suicide tendencies.
Also worth noting is the relationships growing with Pharma and Insurance companies. I have always said that it would really help the consumer a lot if these two entities could create some contracts amongst themselves instead of it kicking back to the consumer so much of the time. Interesting read below when you see a subsidiary of Humana joining Eli Lilly in the “data selling” epidemic. It’s all called “research” and sure there’s some of that in there with everyone and their big data today but the “price” of what this research calls for and what “value” it does or does not have is the question. Humana subsidiary, ComprehensiveHealth Insights, as they advertise on their web site will be working with Eli Lilly.
Pharma and Health Insurance Companies Pairing Up, Humana’s Analytics Subsidiary and Lilly To Figure Out How to Save (Make) Money and Provide Better Patient Care–Selling Research Data That Competes With FDA Sentinel Initiative
So this kind of looks like with trying to find revenue replacements, we can probably look for even more of this as Humana is not alone and actually United HealthCare is the king of data selling with health insurers, even to where Mayo is doing some quasi type commercials for them as well as they want/need money to expand. So again interesting to see where this leads when they all follow the data, and of course “the money”. BD
Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has launched its Duloxetine Hydrochloride Delayed-release (HCl DR) Capsules 20 mg, 30 mg and 60 mg strengths. The Company received final approval to market its Duloxetine HCl DR Capsules USP, 20 mg, 30 mg, 40 mg and 60 mg strengths from the United States Food and Drugs Administration (FDA) yesterday.
Lupin's Duloxetine HCl DR Capsules 20 mg, 30 mg and 60 mg strengths are the generic equivalent of Eli Lilly & Company's (Lilly) Cymbalta(R) Delayed-release Capsules 20 mg, 30 mg and 60 mg.
Duloxetine HCl DR Capsules are indicated for the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD) and management of neuropathic pain (DPNP) associated with diabetic peripheral neuropathy.
Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies.